Relationship between Serum ANXA2,ANXA3 and the Efficacy of Chemotherapy in Patients with Metastatic Colorectal Cancer
Objective:To investigate the relationship between serum annexin(ANX)A2,ANXA3 and the efficacy of chemotherapy in patients with metastatic colorectal cancer(mCRC).Methods:90 mCRC patients who were admitted to the Affiliated Hospital of Xuzhou Medical University from January 2019 to October 2020 were selected,patients were divided into non-remission group and remission group according to the efficacy of mFOLFOX6 chemotherapy combined with cetuximab.Serum ANXA2 and ANXA3 levels were detected by enzyme-linked immunosorbent assay.Using univariate,multivariate logistic regression analysis,and receiver operating characteristic(ROC)curve analysis,respectively,the influencing factors of unresponsive chemotherapy in mCRC patients and the predictive value of serum ANXA2 and ANXA3 on unresponsive chemotherapy in mCRC patients.Results:The objective remission rate of 90 mCRC patients was 58.89％(53/90).Univariate analysis showed that statistical differences between the two groups in terms of age,ileocecal tumor,TNM stage,Zubrod-Eastem Tumor Assistance Group-World Health Organization score(ZPS),treatment goal,ANXA2 and ANXA3(P＜0.05).Multivariate Logistic regression analysis showed that,ileocecal tumor,TNM stage Ⅳ,ZPS score 1-2 and increased ANXA2 and ANXA3 were independent risk factors of non-remission in mCRC patients(P＜0.05).The ROC curve analysis showed that the area under the curve(AUC)predicted by serum ANXA2 was 0.787.The ROC curve analysis showed that the AUC that predicted by ANXA3 was 0.791,and that predicted by serum ANXA2 and ANXA3 was 0.904.The AUC predicted by serum ANXA2 and ANXA3 was the largest(P＜0.05).Conclusion:Increase serum ANXA2 and ANXA3 levels are independent risk factors of chemotherapy non-remission in mCRC patients,which can affect the efficacy of chemotherapy in mCRC patients,and combination of the two has a higher value in predicting chemotherapy non-remission in mCRC patients.
NETL
NSTL
万方数据
维普
